Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Total Current Liabilities (2016 - 2025)

vTv Therapeutics' Total Current Liabilities history spans 12 years, with the latest figure at $6.6 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 27.81% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $6.6 million, up 27.81%, while the annual FY2025 figure was $6.6 million, 27.81% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $6.6 million at vTv Therapeutics, down from $10.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $12.7 million in Q1 2022 and bottomed at $4.3 million in Q1 2025.
  • The 5-year median for Total Current Liabilities is $7.6 million (2022), against an average of $7.7 million.
  • The largest annual shift saw Total Current Liabilities crashed 56.88% in 2021 before it skyrocketed 146.03% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $8.5 million in 2021, then decreased by 9.3% to $7.7 million in 2022, then surged by 37.77% to $10.6 million in 2023, then crashed by 51.07% to $5.2 million in 2024, then increased by 27.81% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Total Current Liabilities are $6.6 million (Q4 2025), $10.2 million (Q3 2025), and $5.3 million (Q2 2025).